Background: Optimal management of the endometrium in patients with oestrogen receptor-positive breast cancer taking extended tamoxifen therapy (for 10 years) remains uncertain. A meta-analysis was performed to determine the cumulative risk ratio (RR) for endometrial malignancy following extended compared with standard tamoxifen treatment. A systematic review was undertaken to identify whether routine endometrial surveillance in patients receiving tamoxifen is associated with earlier detection and reduced incidence of endometrial malignancy.
Introduction
Tamoxifen remains the standard adjuvant hormone treatment for premenopausal women with oestrogen receptor (ER)-positive breast cancer 1 . The concept of 5 years as the optimal duration of adjuvant tamoxifen has been challenged recently, with a shift to extended therapy for a total of 10 years in high-risk women 2, 3 . The benefits of extended therapy, in terms of reduced local recurrence and improved breast cancer-free survival, were originally identified in the large ATLAS (Adjuvant Tamoxifen: Longer Against Shorter) trial 4 and were subsequently confirmed in British aTTom (Adjuvant Tamoxifen: To Offer More?) data 5 . Patients who derive the greatest benefit from extended tamoxifen therapy include younger patients with high-risk disease 6, 7 .
Tamoxifen is classified as a selective ER modulator. The benefits of tamoxifen in breast cancer are due to its antagonistic effect on the α-ER in breast tissue. However, agonistic effects on the β-ER in the endometrium are associated with an increased incidence of endometrial abnormalities including hyperplasia, atypia and malignancy 8, 9 . Previous studies 10, 11 have shown that the uterotrophic effects of tamoxifen are both dose-and duration-dependent. There currently is little evidence examining the increased risk of endometrial malignancy in patients receiving tamoxifen for 10 years (extended therapy).
The value of uterine surveillance for patients receiving tamoxifen remains a source of debate 12, 13 . Current international guidelines clearly state that all patients require pretreatment counselling regarding the associated risk of endometrial malignancy and are advised to report any abnormal gynaecological symptoms, primarily abnormal vaginal bleeding, that may develop 14, 15 . There is agreement that all patients receiving tamoxifen who experience abnormal gynaecological symptoms should be investigated appropriately 14, 15 . It remains uncertain, however, how asymptomatic patients should be approached. Routine screening of asymptomatic women on tamoxifen therapy is not currently recommended. This is based on evidence from patients receiving tamoxifen for a total of 5 years, and the recommendation might need re-evaluation in the era of extended treatment. The most appropriate method of surveillance also remains controversial. Assessment of endometrial thickness (ET) using transvaginal ultrasonography (TVUS) is non-invasive and accessible. However, its accuracy is low as tamoxifen stimulates subendometrial gland enlargement and so ET may also be increased in the absence of malignancy 16, 17 .
The aim of the present review was twofold. The first objective was to perform a meta-analysis to determine the cumulative risk ratio (RR) for endometrial malignancy in extended compared with standard adjuvant tamoxifen therapy for breast cancer. The second was to undertake a systematic review of evidence for the accuracy and value of routine endometrial surveillance in patients receiving tamoxifen.
Methods
This review was performed in keeping with PRISMA standards 18 . A systematic literature search of the Cochrane Library, PubMed and MEDLINE databases was undertaken. The primary aim of the first search was to identify the risk of endometrial malignancy in the setting of extended tamoxifen therapy. The aim of the second search was to identify the efficacy of routine endometrial surveillance in identifying endometrial malignancy in all patients receiving tamoxifen, as no study has yet looked specifically at surveillance during extended tamoxifen therapy.
Search strategy, study inclusion and data extraction for endometrial malignancy risk
The search was limited to prospective RCTs reporting on the endometrial malignancy rate following 10 years of adjuvant tamoxifen for breast cancer compared with 5 years of treatment. The search was performed using the following search algorithm: 'tamoxifen' AND 'extended' AND 'endometrial cancer' OR 'endometrial abnormality' OR 'uterine cancer' OR 'uterine abnormality'. There was no restriction on the date of publication; the latest search was carried out in March 2016. Two authors independently examined the title and abstract of citations. Full texts of potentially eligible trials and studies were obtained, and disagreements regarding suitability for inclusion were resolved by discussion. Reference lists of retrieved papers were further screened for additional eligible publications, as were relevant guideline documents. Inclusion criteria comprised English-language studies, and those that reported outcomes related to endometrial abnormalities and pathologically confirmed malignancy. Publications reporting on the same series of patients were identified and only the most recent data were included. The methodological quality of included RCTs was assessed using the Cochrane Collaboration's tool for assessing RCT risk of bias 19 .
Data extracted from included RCTs were: year of publication, enrolment period, total number of included patients, number of patients on extended therapy, duration of extended therapy, dose of tamoxifen prescribed and Values in parentheses are percentages.
total follow-up interval. Outcome data extracted included: breast cancer local recurrence rates, disease-specific and overall mortality rates and, specifically, the incidence of endometrial malignancy.
Search strategy, study inclusion and data extraction for endometrial surveillance
The search was performed using the following search algorithm: 'tamoxifen' AND 'asymptomatic' AND 'endometrial cancer' OR 'endometrial abnormality' OR 'uterine cancer' OR 'uterine abnormality' AND 'surveillance'. Included were prospective original studies, published in English, that reported on the identification of endometrial abnormalities and malignancy in patients receiving tamoxifen during active endometrial surveillance. There was no restriction on the date of publication. Screening of potential publications was performed as described above. Studies describing 'one-off' endometrial screening in a cross-sectional design were excluded. Studies that did not report on endometrial malignancy rates were excluded. The Newcastle-Ottawa quality assessment scale for non-randomized cohort studies was applied to determine the quality of each eligible study objectively. Points were awarded for patient selection (maximum 4 points), comparability of cohorts (maximum 2 points) and outcome assessment (maximum 3 points), and summed to give an overall quality rating with a maximum of 9 points 20 .
Data extracted from suitable studies included: study design; year of publication; enrolment period; total number of included patients; number of patients on extended therapy; duration of extended therapy and dose of tamoxifen prescribed; mean follow-up interval where available; surveillance test used; interval of surveillance; and incidence of normal, benign, atypical or malignant endometrial findings. Because of the significant heterogeneity in study design, study endpoints and methods of endometrial surveillance among included studies, meta-analysis of the benefits of endometrial surveillance was not possible.
Statistical analysis
A Mantel-Haenszel random-effects model was used to compute the RR and 95 per cent c.i. for malignancy in extended compared with standard adjuvant tamoxifen therapy for breast cancer. The decision to use a random-effects model was made a priori as a degree of heterogeneity between studies was anticipated. The P value for overall effect was calculated using the Z test, and P < 0⋅050 was considered significant. The results of meta-analysis are presented as forest plots. The degree of heterogeneity between studies was expressed as the I 2 statistic. An I 2 value of 0 per cent corresponds to no heterogeneity, 25-49 per cent represents low heterogeneity, 50-74 per cent moderate heterogeneity and 75 per cent or more indicates high heterogeneity between included studies 21 . As a secondary analysis, local recurrence, disease-specific mortality and overall mortality rates were also calculated. Review Manager version 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark) was used to perform the meta-analysis and to generate forest plots. SPSS ® version 22 (IBM, Armonk, New York, USA) was used to summarize data relating to endometrial surveillance.
Results

Risk of endometrial malignancy
The initial literature search identified 282 citations, of which 190 articles were duplicates, leaving 92 for analysis. Total Heterogeneity: τ 2 = 0·05; χ 2 = 5·07, 3 d.f., P = 0·17; I 2 = 41% Test for overall effect: Z = 4·55, P < 0·001 Following title and abstract review, a further 86 studies were excluded (Fig. 1) . Finally, two studies were excluded after full-text article assessment, leaving a total of four RCTs that contained sufficient detail or met the inclusion criteria (Fig. 1) . No studies were excluded based on quality assessment.
Study characteristics and quality assessment
The four RCTs had an enrolment period from 1978 to 2005 (Table 1 ). In total, these trials included 21 361 patients, of whom 7652 (35⋅8 per cent) received extended therapy. All studies scored highly on quality assessment. Three studies 3 -5 compared extended (10 years) adjuvant tamoxifen therapy in the setting of ER-positive breast cancer with standard (5-year) therapy with or without placebo. One study 6 compared indefinite tamoxifen therapy at a 10-year interval with 5 years of treatment. Follow-up for each study ranged from a median of 7 to 10 years and a standard 20-mg oral tamoxifen dose was prescribed daily.
The National Surgical Adjuvant Breast and Bowel Project (NSABP) trial 3 enrolled mostly postmenopausal women with small tumours and node-negative disease (75 per cent). ER status was not available in a large number of patients in both ATLAS (41 per cent) and aTTom (61 per cent). After 2 years of therapy in ATLAS, 17 per cent of patients (almost 1 in 5) assigned to extended therapy had stopped taking tamoxifen for a variety of reasons including pulmonary embolism and myocardial ischaemia, but more commonly gynaecological symptoms (vaginal bleeding, endometrial hyperplasia, atypia and, rarely, endometrial malignancy). In aTTom, this figure was 27 per cent (1 in 4) after 3 years of treatment. At 10 years, only 40 per cent of patients randomized to extended therapy in ATLAS were still taking tamoxifen therapy, with similar figures in aTTom. Combined analysis of endometrial risk was subject to low to moderate heterogeneity (I 2 = 41 per cent).
Outcomes of extended adjuvant tamoxifen therapy
The risk of developing endometrial malignancy was significantly higher in patients undergoing extended 10-year tamoxifen therapy than among those receiving therapy for 5 years, with an absolute increased risk from 1⋅5 to 3⋅2 per cent (RR 2⋅29, 95 per cent c.i. 1⋅60 to 3⋅28; P < 0⋅001) (Fig. 2) . In NSABP B-14 3 , the risk ratio was 6⋅84, but 21 of 24 endometrial cancers were International Federation of Gynecology and Obstetrics (FIGO) stage 1 with good to moderate histological grade when diagnosed. In ATLAS 4 , continuing tamoxifen to 10 years was associated with an absolute increase in the 15-year endometrial cancer risk by twofold, and this was seen almost exclusively in postmenopausal patients. This translated into only a 0⋅4 per cent absolute increase in mortality 4 . Similar findings were 22 Prospective cohort Canada 304 304 0 72 20 mg for 5 years Gerber et al. 23 Prospective cohort Germany 345 247 98 60 20 mg for > 2 years Barakat et al. 24 Prospective cohort USA 111 111 0 60 20 mg for 5 years Berlière et al. 25 Prospective observed in aTTom 5 (RR 2⋅28, 1⋅61 to 3⋅22) and the Scottish trial 6 (RR 3⋅42, 0⋅72 to 16⋅22). An overall reduction in local recurrence from 19⋅1 to 17⋅1 per cent was observed with 10-year therapy, but this was not statistically significant (RR 1⋅03, 0⋅84 to 1⋅26; P = 0⋅76). A reduction in disease-specific mortality from 11⋅6 to 10⋅1 per cent was also noted (RR 0⋅94, 0⋅77 to 1⋅16; P = 0⋅58). A reduction in overall mortality of 1⋅7 per cent also did not reach statistical significance (RR 0⋅93, 0⋅85 to 1⋅02; P = 0⋅14) (Fig. 2) .
Endometrial surveillance
A total of 499 studies were identified following the initial search, of which 198 were duplicates, leaving 301 papers for analysis. Following title and abstract review, a further 283 studies were excluded. One additional study was identified by a search of reference lists during full-text article review of the remaining 18 papers. Finally, four studies sufficiently met the inclusion criteria to justify inclusion in this review (Fig. 3) .
Study characteristics and quality assessment
Quality assessment was poor overall. A meta-analysis was not performed owing to significant heterogeneity in study design, study endpoints and methods of endometrial surveillance among the included studies.
Four published studies 22 -25 containing data on endometrial surveillance or screening in the setting of tamoxifen therapy were included ( Table 2 ). All were performed prospectively in patients receiving adjuvant tamoxifen. Only one study 23 compared endometrial surveillance methods in women receiving tamoxifen versus a cohort of patients not receiving tamoxifen. All studies used tamoxifen at a dose of 20 mg for at least 5 years of planned treatment. Duration of follow-up was variable (36-72 months) and the surveillance interval also varied, from 3-monthly 23 , 6-monthly 23, 24 and/or annual 22, 24, 25 assessment.
Modalities and detection rates
TVUS was the most common modality used to assess the endometrium ( Table 3) 22, 23, 25 . Other methods included TVUS with continuous flow Doppler imaging 22 or hysteroscopy and biopsy 24 . A threshold ET on TVUS assessment that was deemed 'abnormal' stimulated further investigation in the form of formal endometrial assessment and biopsy; the cut-off for ET ranged from 4 to 10 mm in the included studies. All benign, atypical and malignant findings reported in Table 3 relate to biopsy-confirmed findings. Only two studies 22, 23 identified malignancy in their cohort. Both used TVUS as a surveillance method. Endometrial malignancy rates of 1⋅8 and 2 per cent respectively were identified. All patients identified as having an endometrial malignancy were symptomatic (vaginal bleeding) and postmenopausal (Table S1, supporting information) 22, 23 .
Transvaginal ultrasonography
Subgroup analysis was performed on two studies 22, 23 that reported on TVUS as a method of endometrial surveillance to assess its value as a single modality for endometrial surveillance in the setting of tamoxifen therapy. This included 551 patients and 2326 TVUS examinations performed over time with an abnormal ET accepted as above 9 mm; seven cases of endometrial cancer were identified. Abnormal TVUS prompted further surgical endometrial assessment and a biopsy in 391 women (16⋅8 per cent; sometimes more than 1 procedure per patient). On assessment of number needed to treat, it was calculated that 332 TVUS examinations and 56 surgical biopsies needed to be performed to identify one case of endometrial cancer in the setting of adjuvant tamoxifen therapy ( Table 4) . Values in parentheses are percentages. TVUS, transvaginal ultrasonography; ET, endometrial thickness; NNT, number needed to treat.
Discussion
Large trials 4, 5 have shown reduced local recurrence rates and improved survival with 10-year tamoxifen treatment in breast cancer. Extended therapy has greatest benefit in high-risk young patients with a heavy burden of nodal disease 4, 5 . These studies have also demonstrated an increased incidence of endometrial malignancy when tamoxifen therapy is extended to 10 years 4 -6 . In the present meta-analysis, extended adjuvant tamoxifen therapy was associated with a twofold increase in the risk of endometrial malignancy.
The uterotrophic effects associated with tamoxifen are both dose-and duration-dependent 10, 11, 26 . Endometrial cancer in the setting of tamoxifen therapy can, however, occur as early as within 2 years after commencement of therapy 27 . The temporal sequence of uterotrophic effects does not appear to have a linear relationship with the duration of tamoxifen therapy, which makes estimations of when to stop treatment and/or initiate endometrial surveillance difficult 10, 11, 26, 27 . The exact mechanism underlying tamoxifen-induced endometrial cancer is poorly understood, with a number of different biomolecular mechanisms and pathways implicated 28 . The oestrogenic agonistic effect of tamoxifen is thought to be related to upregulation of a variety of signalling pathways, including mitogen-activated protein kinase, c-MYC and insulin-like growth factor 1 28 . DNA damage and mismatch repair has also been suggested owing to genotoxicity and high-frequency p53 mutations, which have a promoter effect on driver genes of sporadic malignancy (PTEN and K-ras) and DNA alterations (microsatellite instability) 28 .
The majority of patients who develop endometrial malignancy on tamoxifen therapy are postmenopausal 3 -6 . The endometrial cancers observed in the trials usually occurred in symptomatic patients and were diagnosed at an early stage and grade, with a mortality risk of less than 1 per cent 3 . Results from the Surveillance, Epidemiology, and End Results (SEER) database identified an increased association between tamoxifen and rare aggressive forms of uterine cancer, most notably malignant mixed Müllerian tumours (MMMTs) 29 . Curtis and colleagues 29 reported that patients on tamoxifen had an observed-to-expected (O/E) ratio of MMMTs of 2⋅29 within the first 4 years after the start of tamoxifen therapy, compared with an O/E ratio of 1⋅45 in the general population. The O/E ratio increased to 11⋅52 and 1⋅48 respectively at 10 years after breast cancer diagnosis, with a median of 7⋅5 years to diagnosis of MMMTs in patients on tamoxifen 29 . At 15 years, uterine cancer-related mortality was observed in 44⋅1 per cent of patients diagnosed with a MMMT, compared with 9⋅5 per cent of those with a uterine adenocarcinoma 29 . These data are based on patients receiving up to and including 5 years of therapy only 29 . Although the majority of tamoxifen-related uterine cancers are low grade and are diagnosed at an early stage, there is a higher incidence of rare uterine sarcomas in patients treated with tamoxifen 29, 30 .
Few studies have investigated the benefit of routine endometrial surveillance in the setting of tamoxifen therapy. The most recent study 22 included in this review was published in 2003, indicating a paucity of research in this area. The studies have not shown any benefit from routine surveillance in patients receiving tamoxifen for 5 years. This is echoed in the guidelines published by both the American 14 and Royal Australian and New Zealand 15 Colleges of Obstetricians and Gynaecologists, which do not recommend routine surveillance in asymptomatic patients receiving tamoxifen. Patients on tamoxifen should be counselled about the risk of endometrial malignancy and advised to report any abnormal gynaecological symptoms promptly, in particular vaginal bleeding. All patients with symptoms should undergo a formal gynaecological assessment.
Tamoxifen increases ET owing to subendometrial gland hypertrophy, and this can occur in the absence of any atypical features. Therefore, unnecessary, costly and potentially harmfully invasive procedures might be initiated 16, 17 . Supporting this concern, in a study of 52 asymptomatic women who underwent hysteroscopy for findings of ET over 9 mm on TVUS, Gerber and colleagues 23 reported four uterine perforations incurred and only one cancer identified.
The current guidelines are based on evidence pertaining to 5 years of tamoxifen therapy. With the evolving role of extended tamoxifen therapy, it is difficult to establish the best management strategy for endometrial surveillance 10, 11, 26 , but low-and high-risk groups have been defined 25 . Premenopausal women appear to represent a low-risk group compared with postmenopausal women 3 -6 , as the risk of tamoxifen-related endometrial cancers appears to be associated exclusively with postmenopausal women 25, 31, 32 . High-risk women are therefore those who are postmenopausal and have an endometrial abnormality at baseline 25, 31 . Berlière and co-workers 25, 31 reported an association between endometrial hyperplasia and atypia and patients who had polyps or other abnormalities identified at baseline pretreatment screening. This did not translate into an increase in the number of endometrial carcinomas actually identified, which may be explained by the fact that such lesions were removed before treatment.
This study has a number of limitations. Endometrial risk in extended tamoxifen therapy as calculated by meta-analysis is dependent on accurate reporting of events in the included trials. Other patient-related factors (family history, obesity) were not addressed and may have acted as confounding variables. Moreover, in analysing the benefit of endometrial surveillance, significant heterogeneity existed between studies in terms of study quality, populations and methods of endometrial surveillance. Numbers of patients included were small compared with those in the large tamoxifen trials; as a result, no cases of endometrial cancer were identified in two studies, which is likely due to a type II error. Different cut-off points for abnormal ET were used and represent an obstacle when comparing the validity of results and methods of endometrial assessment. There appears to be no accepted consensus regarding the definition of an abnormal ET in the setting of tamoxifen therapy. Furthermore, although all four surveillance studies were performed prospectively, none compared the benefit of routine endometrial surveillance versus no surveillance in similar or matched cohorts of patients receiving tamoxifen; this greatly limits the conclusions that can be drawn from the included studies.
Extending tamoxifen therapy to 10 years is associated with a twofold increase in endometrial malignancy compared with the standard 5 years of therapy. Although it is difficult to make clear evidence-based recommendations on endometrial surveillance in the setting of extended therapy because of the sparsity of robust results, a practical approach may be to screen all patients using endometrial ultrasonography after 5 years on tamoxifen. The validity of this approach should be assessed prospectively.
Disclosure
The authors declare no conflict of interest.
